Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
QingReMoShen Granule is a Traditional Chinese Medicine (TCM) formulation developed for the treatment of idiopathic membranous nephropathy (IMN). It is a complex herbal mixture typically administered orally as a granule. In clinical settings, it has been evaluated as an adjunctive therapy alongside Losartan (an angiotensin II receptor antagonist) to assess its efficacy in reducing proteinuria and improving renal function in patients with IMN. The specific herbal ingredients and molecular mechanisms of action have not been publicly disclosed, though the formulation is intended to address the pathological features of IMN through TCM principles such as clearing heat and resolving dampness.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on QingReMoShen Granule.